Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations
Top Cited Papers
- 1 November 2005
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 27 (11) , 1685-1695
- https://doi.org/10.1016/j.clinthera.2005.11.011
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Pharmacokinetics of Bupropion and Its Metabolites in Haemodialysis Patients Who SmokeNephron Clinical Practice, 2004
- REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERSDrug Metabolism and Disposition, 2004
- Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6Pharmacogenetics, 2003
- Combining Bupropion SR With Venlafaxine, Paroxetine, or FluoxetineThe Journal of Clinical Psychiatry, 2002
- Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessationNicotine & Tobacco Research, 2001
- A Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in AdultsAmerican Journal of Psychiatry, 2001
- A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertralineClinical Therapeutics, 1999
- Medical causes of seizuresThe Lancet, 1998
- Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath testBritish Journal of Clinical Pharmacology, 1998
- Disposition of Bupropion in Healthy Volunteers andJournal of Clinical Psychopharmacology, 1990